Clinical trial
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or…
NCT00487786 · Achieve Life Sciences, Industry · Completed
Key facts
| NCT number | NCT00487786 |
|---|---|
| Title | Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer |
| Official title | A Phase 1 Study Evaluating A Second Generation Antisense Oligonucleotide (OGX 427) That Inhibits Heat Shock Protein 27 (Hsp27 |
| Lead sponsor | Achieve Life Sciences, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | OGX-427, Docetaxel |
| Enrollment | 64 |
| Start date | Jun 1, 2007 |
| Primary completion | Jun 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Jun 19, 2007 |
| Last update posted | Jan 18, 2016 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: